Next-Gen Therapies: Powered by Multi-Omics
As therapies become increasingly targeted and personalised, success depends on understanding the disease biology driving patient-to-patient variation. Identifying likely responders, understanding mechanisms of non-response and generating robust translational evidence are increasingly critical to therapeutic development and clinical trial design.
Join leaders from pharma, biotech, academia and investment for keynote talks from Richard Goodwin (AstraZeneca) and Professor Sheeba Irshad (King's College London / Guy's & St Thomas'), followed by a panel discussion moderated by Tim Haines, Executive Director, Abingworth. We will explore how deeper biological insight can de-risk therapeutic development and accelerate translation to patient impact.
Learn how King's new Smart Trials Hub is helping researchers and industry partners address these challenges through integrated multi-omics capabilities, translational expertise, and facilitating access to patient cohorts, human tissues and clinical trial infrastructure.
Hosted by King's College London, Canary Wharf Group and ELRIG, this event showcases the opportunities created through collaboration across London's life sciences ecosystem.
Why Attend
Gain insights from industry and translational research leaders.
Explore how multi-omics is transforming patient stratification, biomarker discovery and clinical trial design.
Connect with leaders from pharma, biotech, academia, healthcare and investment.
Discover how integrated translational capabilities can accelerate therapeutic development and de-risk innovation.